Show simple item record

dc.contributor.authorBoard, Ruth E
dc.contributor.authorThistlethwaite, Fiona C
dc.contributor.authorHawkins, Robert E
dc.date.accessioned2009-07-07T16:34:06Z
dc.date.available2009-07-07T16:34:06Z
dc.date.issued2007-02
dc.identifier.citationAnti-angiogenic therapy in the treatment of advanced renal cell cancer. 2007, 33 (1):1-8 Cancer Treat. Rev.en
dc.identifier.issn0305-7372
dc.identifier.pmid17071006
dc.identifier.doi10.1016/j.ctrv.2006.08.003
dc.identifier.urihttp://hdl.handle.net/10541/72889
dc.description.abstractMetastatic renal cell cancer is associated with a poor prognosis and is resistant to traditional chemotherapy agents. The majority of tumours are associated with inactivation of the von Hippel-Lindau gene and subsequent overexpression of proangiogenic factors, including vascular endothelial growth factor (VEGF). Drugs targeting these pathways have undergone clinical testing in renal cell cancer with encouraging results. This type of therapy is set to revolutionise the treatment of renal cell cancer and this review outlines recent evidence from clinical trials investigating the most promising of these agents.
dc.language.isoenen
dc.subjectKidney Canceren
dc.subject.meshAngiogenesis Inhibitors
dc.subject.meshAntibodies, Monoclonal
dc.subject.meshCarcinoma, Renal Cell
dc.subject.meshCarrier Proteins
dc.subject.meshHumans
dc.subject.meshKidney Neoplasms
dc.subject.meshVascular Endothelial Growth Factor A
dc.subject.meshVascular Endothelial Growth Factor Receptor-1
dc.titleAnti-angiogenic therapy in the treatment of advanced renal cell cancer.en
dc.typeArticleen
dc.contributor.departmentCancer Research UK Department Medical Oncology, Christie Hospital, Manchester M20 4BX, UK. Ruth.Board@christie-tr.nwest.nhs.uken
dc.identifier.journalCancer Treatment Reviewsen
html.description.abstractMetastatic renal cell cancer is associated with a poor prognosis and is resistant to traditional chemotherapy agents. The majority of tumours are associated with inactivation of the von Hippel-Lindau gene and subsequent overexpression of proangiogenic factors, including vascular endothelial growth factor (VEGF). Drugs targeting these pathways have undergone clinical testing in renal cell cancer with encouraging results. This type of therapy is set to revolutionise the treatment of renal cell cancer and this review outlines recent evidence from clinical trials investigating the most promising of these agents.


Files in this item

This item appears in the following Collection(s)

Show simple item record